Quarterlies round-up: Becton Dickinson and Conmed feel effects of litigation while Guidant regroups as DES sales bite
This article was originally published in Clinica
Executive Summary
While Baxter recorded a healthy 10% increase in second quarter revenues compared with the same period last year, its overall performance was offset by special charges related to the company's restructuring initiatives announced in January 2004. These initiatives include eliminating 8% of its current global workforce, or approximately 4,000 positions. Around 50% of these job cuts will be made in the US. The company also reduced its plasma production by a further 400,000 litres, or 13%, on an annual basis and additional plasma collection centres have been closed as part of the company's streamlining process. The implementation of these restructuring plans has led to a total after-tax charge of $394m in the second quarter, resulting in a $170m net loss for that period.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.